20th Anniversary AATOD Conference
Approximately 1,300 individuals participated in AATOD’s 20th Anniversary National Conference, which convened against the magical backdrop of Orlando, Florida. The participants included treatment providers from across the country discussing both U.S. and international issues in addition to government officials, patient advocates and researchers. The Conference continued in its tradition of offering intensive pre conference sessions, updating courses for clinicians and patient advocates. It also provided two groundbreaking sessions, focusing on opioid treatment in correctional settings in addition to providing program managers with a better understanding of implementing risk management measures in the OTP setting.
This webpage contains a significant amount of information, which was included as part of the workshop presentations. This is the first time such information is being made available.
The Conference achieved its objectives in advancing a number of AATOD’s critical initiatives, including expanding access to methadone treatment through the criminal justice setting and working to better understand the impact that prescription opioids is having on OTP admission.
This anniversary conference provided a critical link between past conference successes and our next event, which is scheduled to convene during April 2006 in Atlanta, Georgia.
2004 Conference Literature
2004 Conference Handouts
2004 Conference Photos
2004 Conference Presentations
40th Anniversary of Opioid Agonist Pharmacotherapy for Heroin and Related Opiate Addiction:Perspectives and Expectations for the Future (Powerpoint)
This presentation was made by Mary Jeanne Kreek, MD (Professor and Head, The Laboratory of the Biology of Addictive Diseases, Rockefeller University, New York, NY) during the Middle Plenary Session entitled “Research to Practice: Using Evidence-Based Methods in Community Treatment and Drug Court Settings. (October 19, 2004)
2004 Conference Speeches
Remarks Made by Mark Parrino, AATOD President, during the Plenary Session entitled “National Drug Policy: Reducing Demand by Improving Treatment Access” October 19, 2004